Bausch & Lomb made pharma news with the decision of going public as early as the end of this year, the Wall Street Journal reported, citing people familiar with the company’s thinking.
The eye-care company’s Chief Executive Brent Saunders told Reuters last October that he was setting sights on an IPO for the company “in the next couple of years.”
Bausch & Lomb and its private equity owner Warburg Pincus declined to comment on this pharma news.
Previously traded on the New York Stock Exchange, the Rochester, New York-based company was acquired for $4.5 billion by Warburg Pincus in late 2007 after falling out of Wall Street’s favor because of product recalls, big charges and restatements of earnings.
Bausch & Lomb agreed to buy Ista Pharmaceuticals Inc ISTA.O in March for about $500 million in cash to broaden its portfolio of eye health products.
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity